We have constructed vaccinia virus recombinants expressing dengue virus proteins from cloned DNA for use in experimental immunoprophylaxis. A recombinant virus containing a 4.0-kilobase DNA sequence that codes for three structural proteins, capsid (C), premembrane (pre-M), and envelope (E), and for nonstructural proteins NS1 and NS2a produced authentic pre-M, E, and NS1 in infected CV-1 cells. Mice immunized with this recombinant were protected against an intracerebral injection of 100 50% lethal doses of dengue 4 virus. A recombinant containing only genes C, pre-M, and E also induced solid resistance to challenge. Deletion of the putative C-terminal hydrophobic anchor of the E glycoprotein did not result in secretion of E from recombinant-virus-infected cells. Recombinants expressing only the E protein preceded by its own predicted N-terminal hydrophobic signal or by the signal of influenza A virus hemagglutinin or by the N-terminal 71 amino acids of the G glycoprotein of respiratory syncytial virus produced glycosylated E protein products of expected molecular sizes. These vaccinia virus recombinants also protected mice.
Dengue virus infections are a steadily worsening health problem in tropical regions of the world. It has been estimated that more than 100 million dengue illnesses now occur each year (5) . There are four dengue virus serotypes, which together form a subgroup within the flavivirus family. Primary dengue virus infection often produces a painful, debilitating, but nonfatal febrile illness. A severe form of dengue virus infection known as hemorrhagic fever/shock syndrome has occurred recently with increasing frequency in regions where several different dengue serotypes have circulated simultaneously or sequentially. Despite more than 40 years of effort, safe and effective dengue virus vaccines are not available.
The dengue virus genome consists of a single strand of positive-sense RNA. Our laboratory has cloned and sequenced cDNA fragments encompassing the full length of a Caribbean isolate of dengue 4 virus, strain 814669 (7, 14) . The genome contains 10,644 nucleotides, 96% of which make up a single open reading frame encoding a polyprotein 3,386 amino acids in length. The genome was mapped on the basis of its homology to that of other flaviviruses. The genes encoding the three structural proteins, capsid (C), membrane (M), and envelope (E), of dengue virus are located at its 5' end, followed by those of nonstructural proteins NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5. Following synthesis of a large polyprotein, the individual viral proteins are thought to be released through cleavage by specific proteases (3) . C and M are internal proteins of the virion; M is formed through cleavage of a precursor glycoprotein designated pre-M (11) . The E glycoprotein binds to cellular receptors and interacts with neutralizing antibody (10) . Parenteral administration of monoclonal antibodies to the dengue 2 virus E glycoprotein protects mice against subsequent dengue 2 virus challenge (6) . The nonstructural glycoprotein NS1, originally detected as a soluble complement-fixing * Corresponding author.
antigen, has been identified on the surface of infected cells (1) . Immunization with purified dengue 2 virus NS1 has been shown to protect mice against dengue 2 virus challenge (9).
We recently described a recombinant vaccinia virus containing a dengue 4 virus cDNA segment that codes for C, pre-M, E, NS1, and NS2a (15) . The cDNA was inserted into the thymidine kinase (TK) locus of WR strain vaccinia virus, under control of the vaccinia virus early/late P7.5 promoter, through use of the pSC11 transfer vector (2) . This recombinant virus, vC-M-E-NS1-NS2a, produces apparently authentic pre-M, E, and NS1 glycoproteins. Immunization of cotton rats induced a weak antibody response to NS1, but antibody to pre-M or E was not detected. We tested this recombinant virus for its ability to protect weanling mice against an intracerebral (i.c. Fig. 2A and B, recombinant vC-M-E-NS1-NS2a synthesized pre-M, E, and NS1 glycoproteins of approximately 20, 55 to 60, and 40 to 46 kilodaltons (kDa), respectively, similar in estimated molecular masses to the authentic dengue virus proteins. The reduction in estimated molecular mass observed after endo-F treatment was the same for both recombinant and authentic proteins. Recombinant vC-M-E produced apparently authentic pre-M. The E proteins produced by recombinants vC-M-E, vE, and vHA/ E were apparently identical in size and showed approximately the same size reduction following endo-F treatment (Fig. 2B ). This suggests that both the predicted dengue virus E signal and the signal of influenza A virus hemagglutinin are capable of directing the intracellular processing of E. The deglycosylated E proteins were approximately 3 to 4 kDa smaller than identically treated authentic E, consistent with the absence of approximately 40 amino acids from the C-terminus of the recombinant E proteins. T'he vRSVG/E envelope protein had an estimated molecular mass of approximately 62 kDa. a size increase consistent with the expression of a protein containing the N-terminal 71 amino acids of RSV G fused to the N-terminus of E. This chimeric protein was also glycosylated. as shown by reduction in size to approximately 53 kDa after treatment with endo-F.
Immunoprecipitation of medium from radiolabeled CV-1 cells infected with vC-M-E-NS1-NS2a revealed a single labeled protein of slightly higher molecular mass than the NS1 present in lysates of infected cells ( Fig. 2A . medium. expressed on the surface of infected cells, while dengue virions are not released by budding, and E is not found on the cell surface (10) .
Vaccinia virus recombinants containing only dengue 4 virus structural genes were tested for their ability to protect weanling mice against an i.c. dengue 4 virus challenge. All mice immunized with either one dose or two doses of vC-M-E remained free of disease following dengue 4 virus challenge (Table 1) . Immunization with recombinants expressing only the E glycoprotein also protected mice against fatal encephalitis. All of the mice immunized with either one or two doses of vHA/E remained free of disease. In contrast, most of the animals immunized with vE or vRSVG/E developed transient signs of mild encephalitis, but all survived challenge. Less than half of the fully protected mice developed serum antibodies to dengue virus structural proteins following immunization, as measured by enzyme-linked immunosorbent assay with purified virions as the antigen (data not shown). Antibodies detected were of low titer.
The high degree of protection induced in mice by vaccinia virus recombinants expressing dengue 4 virus structural proteins is clearly of interest in terms of dengue virus vaccine development. However, Deubel et al. have reported that a vaccinia virus recombinant containing all three dengue 2 virus structural protein genes failed to prevent viremia in Cynomolgus monkeys following homotypic challenge (4). We are pursuing our investigation of the immune mechanisms responsible for protection in mice in order to determine the requirements for protective efficacy. We hope that an understanding of how vaccinia virus recombinants protect mice may prove useful in the development of recombinant dengue virus vaccines effective in experimental primates and in humans.
